National Health Investors, Inc. cash flow to debt ratio of 20.64% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

National Health Investors, Inc.'s free cash flow has increased 14.46% from $192.44M last year to $220.26M, signaling increasing performance

National Health Investors, Inc.'s debt to equity ratio is 0.82, which means that the company's assets are unhealthy financed, signaling financial risk.

National Health Investors, Inc.'s debt has decreased relative to shareholder equity from 0.84 last year to 0.82 today, signaling strengthened financials

National Health Investors, Inc. has a net debt to EBITDA ratio of 4.06x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

National Health Investors, Inc.'s interest coverage ratio of 4.46 indicates that earnings with good margin can cover interest payments on company debt

National Health Investors, Inc.'s profit margin was 41.17% last year and is 38.47% this year, signaling decreasing performance

National Health Investors, Inc.'s short-term assets of $310.22M exceed its short-term liabilities of $125.00M

National Health Investors, Inc.'s return on assets of 5.63% is higher than the 5.00% threshold, indicating efficient asset utilization

National Health Investors, Inc.'s return on equity of 10.96%, is lower than 15.00%, indicating bad performance

National Health Investors, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

National Health Investors, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

National Health Investors, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

National Health Investors, Inc. has a free cash flow yield of 6.79%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

National Health Investors, Inc.'s yearly earnings has increased 3.04% since last year from $137.99M to $142.18M, signaling increasing performance

National Health Investors, Inc.'s yearly revenue has increased 12.93% since last year from $335.18M to $378.53M, signaling increasing performance

ROIC 6.91% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

National Health Investors, Inc.'s 3-year revenue CAGR of 10.81% is positive, indicating growing revenue over the past 3 years

National Health Investors, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

National Health Investors, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

National Health Investors, Inc. is overvalued relative to its fair value price of 28.11 based on Base Cash Flow Valuation (DCF) model

National Health Investors, Inc. has an earnings yield of 5.15%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

National Health Investors, Inc. is overvalued relative to its fair value price of 17.64 based on Base EBITDA Valuation model

National Health Investors, Inc. has an EV/EBITDA ratio of 15.56x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

National Health Investors, Inc. is overvalued relative to its fair value price of 60.52 based on Base Earnings Fair Value model

National Health Investors, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

National Health Investors, Inc. has a price-to-book ratio of 2.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

National Health Investors, Inc. has a price-to-sales ratio of 7.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue